Abstract
Herpes simplex viruses (HSV) possess unique functions as both oncolytic vectors and vaccines capable of initiating an innate host antitumor immune response and have been developed for the gene therapy of cancer. Modifications of viral genes encoding pathogenicity and immunogenicity proteins and insertion of eukaryotic immune enhancing genes have resulted in viral strains with selective tumor oncolytic and potent immunization potential with an acceptable safety profile and no neurotoxicity. Several modified HSV vectors are currently in clinical trials, with the most experience in the treatment of advanced melanoma. In this chapter, we discuss the basic biology of HSV, describe the origin of individual oncolytic HSV strains in clinical use, and present the results of clinical trials for melanoma and other human cancers.
| Original language | English (US) |
|---|---|
| Title of host publication | Gene Therapy of Cancer |
| Subtitle of host publication | Translational Approaches from Preclinical Studies to Clinical Implementation: Third Edition |
| Publisher | Elsevier Inc. |
| Pages | 213-223 |
| Number of pages | 11 |
| ISBN (Print) | 9780123942951 |
| DOIs | |
| State | Published - Aug 2013 |
| Externally published | Yes |
Keywords
- Advanced cancer
- Herpes simplex virus
- Immunotherapy
- Oncolysis
- Vaccin
ASJC Scopus subject areas
- Dentistry(all)
- Medicine(all)
